JP2023553935A5 - - Google Patents
Info
- Publication number
- JP2023553935A5 JP2023553935A5 JP2023535332A JP2023535332A JP2023553935A5 JP 2023553935 A5 JP2023553935 A5 JP 2023553935A5 JP 2023535332 A JP2023535332 A JP 2023535332A JP 2023535332 A JP2023535332 A JP 2023535332A JP 2023553935 A5 JP2023553935 A5 JP 2023553935A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- mrna
- amino acid
- polypeptide
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063124060P | 2020-12-11 | 2020-12-11 | |
| US63/124,060 | 2020-12-11 | ||
| US202063130104P | 2020-12-23 | 2020-12-23 | |
| US63/130,104 | 2020-12-23 | ||
| US202163165636P | 2021-03-24 | 2021-03-24 | |
| US63/165,636 | 2021-03-24 | ||
| US202163275424P | 2021-11-03 | 2021-11-03 | |
| US63/275,424 | 2021-11-03 | ||
| PCT/US2021/062922 WO2022125968A1 (en) | 2020-12-11 | 2021-12-10 | Polynucleotides, compositions, and methods for genome editing involving deamination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023553935A JP2023553935A (ja) | 2023-12-26 |
| JP2023553935A5 true JP2023553935A5 (cg-RX-API-DMAC10.html) | 2025-09-04 |
Family
ID=80118959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023535332A Pending JP2023553935A (ja) | 2020-12-11 | 2021-12-10 | 脱アミノ化を伴うゲノム編集のためのポリヌクレオチド、組成物、及び方法 |
Country Status (13)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3220738A1 (en) * | 2021-05-21 | 2022-11-24 | Beam Therapeutics Inc. | Base editing of transthyretin gene |
| TW202317764A (zh) * | 2021-06-10 | 2023-05-01 | 美商英特利亞醫療公司 | 用於基因編輯之包含內部連接子之經修飾引導rna |
| EP4426836A1 (en) * | 2021-11-03 | 2024-09-11 | Intellia Therapeutics, Inc. | Modified guide rnas for gene editing |
| EP4426822A2 (en) * | 2021-11-03 | 2024-09-11 | Intellia Therapeutics, Inc. | Polynucleotides, compositions, and methods for genome editing |
| WO2024006955A1 (en) | 2022-06-29 | 2024-01-04 | Intellia Therapeutics, Inc. | Engineered t cells |
| EP4638783A2 (en) | 2022-12-22 | 2025-10-29 | Intellia Therapeutics, Inc. | Methods for analyzing nucleic acid cargos of lipid nucleic acid assemblies |
| WO2024227082A1 (en) * | 2023-04-26 | 2024-10-31 | Vijay Sankaran | Base-editing perturbation screens and uses thereof |
| WO2025038637A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| TW202515994A (zh) | 2023-08-14 | 2025-04-16 | 美商英特利亞醫療公司 | 用於對cd70進行基因修飾之組合物及方法 |
| WO2025081064A2 (en) * | 2023-10-11 | 2025-04-17 | Illumina, Inc. | Thermophilic deaminase and methods for identifying modified cytosine |
| KR20260062985A (ko) * | 2023-10-13 | 2026-05-07 | 스마트셀라 솔루션즈 아베 | 중간엽 줄기세포를 이용한 비변형 mRNA 작제물의 전달을 위한 방법 및 조성물 |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| IL330230A (en) | 2023-12-20 | 2026-08-01 | Intellia Therapeutics Inc | Engineered T cells |
| WO2025255308A1 (en) | 2024-06-07 | 2025-12-11 | Intellia Therapeutics, Inc. | Cd8 co-receptor chimeric polypeptides in tcr cell therapy |
| TW202617987A (zh) * | 2024-06-26 | 2026-05-01 | 美商英特利亞醫療公司 | 用於基因體編輯之經修飾之嚮導rna |
| WO2026143185A1 (en) | 2024-12-23 | 2026-07-02 | Ensoma Aps | Engineered rna-guided dna-binding polypeptides |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| ATE515510T1 (de) | 1991-12-24 | 2011-07-15 | Isis Pharmaceuticals Inc | Durch dna-abschnitte unterbrochene modifizierte oligonukleotide |
| EP0760008A1 (en) | 1994-05-19 | 1997-03-05 | Dako A/S | Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis |
| WO2001075436A1 (en) | 2000-04-03 | 2001-10-11 | Board Of Trustees Of The Leland Stanford Junior University | A method for protein structure alignment |
| WO2006007712A1 (en) | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
| US7774185B2 (en) | 2004-09-14 | 2010-08-10 | International Business Machines Corporation | Protein structure alignment using cellular automata |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| ES2887254T3 (es) | 2013-03-08 | 2021-12-22 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| US10059655B2 (en) | 2013-12-19 | 2018-08-28 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| AU2016226077B2 (en) | 2015-03-03 | 2021-12-23 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases with altered PAM specificity |
| DK4276189T3 (da) | 2015-09-21 | 2026-05-26 | Trilink Biotechnologies Llc | Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe |
| ES3030658T3 (en) * | 2016-03-30 | 2025-07-01 | Intellia Therapeutics Inc | Lipid nanoparticle formulations for crispr/cas components |
| JP2019515914A (ja) | 2016-04-22 | 2019-06-13 | インテリア セラピューティクス,インコーポレイテッド | 転写因子4内のトリヌクレオチドリピートと関連する疾患の治療のための組成物および方法 |
| EP3551757A1 (en) | 2016-12-08 | 2019-10-16 | Intellia Therapeutics, Inc. | Modified guide rnas |
| JP7383478B2 (ja) | 2016-12-22 | 2023-11-20 | インテリア セラピューティクス,インコーポレイテッド | アルファ1アンチトリプシン欠乏症を治療するための組成物および方法 |
| WO2019041296A1 (zh) * | 2017-09-01 | 2019-03-07 | 上海科技大学 | 一种碱基编辑系统及方法 |
| EP3688162B1 (en) | 2017-09-29 | 2024-03-06 | Intellia Therapeutics, Inc. | Formulations |
| TWI904069B (zh) | 2017-09-29 | 2025-11-11 | 美商英特利亞醫療公司 | 用於ttr基因編輯及治療attr澱粉樣變性之組合物及方法 |
| JP7832761B2 (ja) | 2018-06-08 | 2026-03-18 | インテリア セラピューティクス,インコーポレイテッド | 遺伝子編集のための修飾されたガイドrna |
| MX2021001070A (es) | 2018-07-31 | 2021-05-27 | Intellia Therapeutics Inc | Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1). |
| JP7541508B2 (ja) * | 2018-08-23 | 2024-08-28 | サンガモ セラピューティクス, インコーポレイテッド | 操作された標的特異的な塩基エディター |
| MX2021003455A (es) | 2018-10-02 | 2021-09-21 | Intellia Therapeutics Inc | Lípidos con amina ionizables. |
| CN113166743B (zh) | 2018-10-15 | 2026-04-07 | 马萨诸塞大学 | Nme2cas9-脱氨酶融合蛋白的可编程dna碱基编辑 |
| CN119285480A (zh) | 2018-12-05 | 2025-01-10 | 英特利亚治疗股份有限公司 | 改性的胺脂质 |
| KR20210116526A (ko) * | 2019-01-16 | 2021-09-27 | 빔 테라퓨틱스, 인크. | 증진된 항-신생물 활성 및 면역억제 내성을 갖는 변형된 면역 세포 |
| MX2021011690A (es) * | 2019-03-28 | 2022-01-06 | Intellia Therapeutics Inc | Composiciones y métodos para la edición del gen ttr y el tratamiento de la amiloidosis attr que comprende un corticosteroide o uso de este. |
| WO2020219876A1 (en) | 2019-04-25 | 2020-10-29 | Intellia Therapeutics, Inc. | Ionizable amine lipids and lipid nanoparticles |
-
2021
- 2021-12-10 EP EP21852000.5A patent/EP4259792A1/en active Pending
- 2021-12-10 CR CR20230305A patent/CR20230305A/es unknown
- 2021-12-10 MX MX2023006876A patent/MX2023006876A/es unknown
- 2021-12-10 WO PCT/US2021/062922 patent/WO2022125968A1/en not_active Ceased
- 2021-12-10 AU AU2021394998A patent/AU2021394998A1/en active Pending
- 2021-12-10 JP JP2023535332A patent/JP2023553935A/ja active Pending
- 2021-12-10 KR KR1020237022781A patent/KR20230129996A/ko active Pending
- 2021-12-10 IL IL303506A patent/IL303506A/en unknown
- 2021-12-10 TW TW110146322A patent/TW202237845A/zh unknown
- 2021-12-10 CA CA3205000A patent/CA3205000A1/en active Pending
-
2023
- 2023-06-09 US US18/332,335 patent/US20240002820A1/en active Pending
- 2023-06-09 CL CL2023001684A patent/CL2023001684A1/es unknown
- 2023-07-07 CO CONC2023/0009114A patent/CO2023009114A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU604634B2 (en) | Dog and horse interferons | |
| JP2024525665A5 (cg-RX-API-DMAC10.html) | ||
| JP7854334B2 (ja) | ファージミドベクター | |
| CA2304254C (en) | Trimerising module | |
| CN111757889A (zh) | 新型CRISPR/Cas12f酶和系统 | |
| JP7663492B2 (ja) | 細胞透過性ペプチド | |
| JP2024533311A5 (cg-RX-API-DMAC10.html) | ||
| CN114615998B (zh) | 缀合物及其用途 | |
| AU2013248928A1 (en) | Peptides for the binding of nucleotide targets | |
| JP2024542995A5 (cg-RX-API-DMAC10.html) | ||
| Freudl et al. | Cloning and molecular characterization of the ompA gene from Salmonella typhimurium | |
| JP2023534924A5 (cg-RX-API-DMAC10.html) | ||
| JP2024511131A5 (cg-RX-API-DMAC10.html) | ||
| JP2022502347A (ja) | 細胞透過性ペプチド | |
| US9222107B2 (en) | REIC-expressing adenovirus vector | |
| US9809632B2 (en) | Universal protein tag for double stranded nucleic acid delivery | |
| CN101524529A (zh) | HNF4α诱导分化治疗人体恶性实体瘤 | |
| EP3741845B1 (en) | Recombinant vaccinia virus and pharmaceutical composition comprising same | |
| WO2025067214A1 (zh) | 一种rna甲基化的编辑系统及其应用 | |
| EP0596969A1 (en) | Igf-ii analogues | |
| CN114438106A (zh) | Rv2779c基因及其表达产物作为抗结核分枝杆菌靶点的应用 | |
| WO2025045078A1 (zh) | 一种用于调控rna甲基化修饰的编辑系统及其应用 | |
| US20250332284A1 (en) | Modified plant virus system for delivery of nucleic acids into mammalian cells | |
| JP7764502B2 (ja) | 環状RNA Circ-ACE2翻訳によるポリペプチド及びその使用 | |
| CN103626863B (zh) | 一种抑制癌细胞生长的短肽及其编码基因 |